ResMed reports record quarterly result
ResMed Inc. (RMD) announced a record quarterly revenue and net income of US$247 million and US$42.1 million respectively for the three months to September 30, 2009. The company said revenue and income were up 13% and 50% on the previous corresponding period.
ResMed said diluted earnings per share for the quarter was US55c, an increases of 53% on the pcp.
The company said Selling, General & Administrative (SG&A) costs increased 8% to US$76.8 million for the September 2009 quarter, over the pcp, while Research and Development (R&D) expenses increased 4% compared to the same period.
ResMed said both expenses were favourably impacted by the appreciation of the U.S. dollar against international currencies.
The company said inventory, at US$175.1 million, increased by US$17.7 million compared to June 30, 2009.
President and CEO, Kieran T. Gallahue, said the company’s favourable mix of product sales and market share gains led to a 19% increase in the Americas over the prior year quarter, resulting in US$134.7 million in revenue.
“Sales outside the Americas were impacted by currency movements, in particular the depreciation of the Euro against the US dollar,” Mr Gallahue said.
“As a result, sales outside the Americas increased by 8% to US$112.3 million, but were up 13% in constant currency terms.”
Mr Gallahue said cash flow from operations for the September quarter was US$64.1 million.
As at 1047 AEDT, ResMed shares were up 10c to $5.50.
Leave a Reply